Skip to main content
KIDS
NASDAQ Industrial Applications And Services

OrthoPediatrics Projects Strong 2026 Growth, Adjusted EBITDA Doubling, and Free Cash Flow Breakeven

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$17.95
Mkt Cap
$446.126M
52W Low
$15.28
52W High
$26.4
52W Position info
17% above low
Off High info
32% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

KIDS sits 17% above its 52-week low of $15.28.

Summary

OrthoPediatrics Corp. filed an investor presentation detailing its full year 2025 financial results and providing strong 2026 guidance, including projected revenue growth, a near-doubling of Adjusted EBITDA, and Free Cash Flow breakeven.


Key Events · Earnings and Guidance · KIDS

  • Reports Full Year 2025 Financial Results

    The company reported $236.3 million in total revenue for full year 2025, representing 15% growth over 2024, with a net loss of ($39.6 million) and diluted EPS of ($1.69).

  • Issues Strong 2026 Financial Guidance

    OrthoPediatrics projects 2026 revenue between $262.0 million and $266.0 million (11% to 13% growth), Adjusted EBITDA of approximately $25.0 million (nearly double 2025's $14.8 million), and anticipates achieving Free Cash Flow breakeven.

  • Highlights Strategic Growth Initiatives

    The investor presentation details ongoing aggressive R&D, strategic acquisitions like Boston Orthotics & Prosthetics, and expansion of its Specialty Bracing (OPSB) division with plans for 18 new markets by 2027.

  • Provides Comprehensive Business Overview

    The filing includes a detailed investor presentation outlining the company's market opportunity, broad product portfolio, commercial execution, and commitment to clinical education in pediatric orthopedics.


Analysis · KIDS · Industrial Applications And Services

This 8-K filing, accompanied by a comprehensive investor presentation, provides a detailed update on OrthoPediatrics' strategic direction and financial outlook. The most significant takeaway is the robust 2026 guidance, which projects substantial growth in Adjusted EBITDA and a move towards Free Cash Flow breakeven. This signals a positive shift towards profitability and improved financial health for the growth-oriented company. The detailed presentation also reinforces the company's strong market position in pediatric orthopedics, aggressive R&D, and strategic expansion plans, which are crucial for long-term value creation.

At the time of this filing, KIDS was trading at $17.95 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $446.1M. The 52-week trading range was $15.28 to $26.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KIDS - Latest Insights

KIDS
Jun 24, 2026, 7:05 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.58
Real-time Price: $19.84 info
Change: +$1.26 (+7%) info
Market Cap: $509.59M info
KIDS
Jun 04, 2026, 4:22 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $18.10
Real-time Price: $19.84 info
Change: +$1.74 (+10%) info
Market Cap: $509.59M info
KIDS
May 01, 2026, 3:45 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $15.61
Real-time Price: $19.84 info
Change: +$4.23 (+27%) info
Market Cap: $509.59M info
KIDS
Apr 30, 2026, 4:20 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $15.36
Real-time Price: $19.84 info
Change: +$4.48 (+29%) info
Market Cap: $509.59M info
KIDS
Apr 20, 2026, 4:57 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $16.65
Real-time Price: $19.84 info
Change: +$3.19 (+19%) info
Market Cap: $509.59M info